Abstract:Abstract Aims We aim to investigate the correlation between high levels of the systemic immune‐inflammation index (SII) and long‐term mortality and major cardiovascular adverse events in advanced chronic heart failure patients with renal dysfunction. Methods and results Seven hundred seventeen advanced chronic heart failure patients with renal dysfunction, who visited the First affiliated hospital of Zhengzhou University from September 2019 to December 2020, were included. All‐cause mortalities (ACM) were selected as primary endpoints and major cardiovascular adverse events (MACEs) as the secondary endpoints. Based on the receiver operating characteristic (ROC) curve and the Youden index, the optimal cut‐off values of SII for ACM and MACEs were 1228 and 1406. In the group where ACM were the primary endpoint, patients were categorized into the low‐SII group (n = 479) and the high‐SII group (n = 238). Patients in the group using MACEs as the secondary endpoint were also categorized into the low‐SII groups (n = 514) and the high‐SII groups (n = 203). Univariate and multivariate COX regression were used to screen the independent predictors for ACM and MACEs, revealing the relationship between SII levels and endpoints. According to the univariate COX analysis, SII was the risk factor (hazard ratio [HR] = 2.144, 95% confidence interval [CI]: 1.565–2.938, P < 0.001) for the ACM subgroup. It was also the risk factor (HR = 1.625, CI: 1.261–2.905, P < 0.001) for the MACEs subgroup. Multivariate COX regression analysis indicated that the occurrence of ACM and MACEs in high‐level SII and low‐level SII patients had statistical differences. The incidence of ACM increased by 70.3% (HR = 1.703; 95% CI: 1.200–2.337; P = 0.002) in patients of the high SII level group, the incidence of MACEs increased by 58.3% (HR = 1.583, 95% CI: 1.213–2.065, P = 0.001). Kaplan–Meier (K‐M) survival analysis further suggested that patients with a high SII level had an increased risk of having ACM (log‐rank P < 0.001) and MACEs (log‐rank P < 0.001) within 30 months. SII could be considered as a novel predictor of the occurrence of ACM and MACEs for patients with advanced chronic heart failure and renal dysfunction. Conclusions This study suggested that SII is a novel independent predictor of mortality in advanced chronic heart failure patients with renal dysfunction, and it should be considered in current clinical management.

Systemic Immune-Inflammatory Index predicts prognosis of patients with COVID-19: a retrospective study

Combined Clinical and Imaging Features Better Predict the Critical Outcomes of Patients with SARS-COV-2.

Prognostic value of the SII Systemic Immune-Inflammation Index a novel biomarker in coronavirus disease 2019 patient?s disease progression to fatality

Prognostic Value of Immune-Inflammatory Index in PSI IV-V Patients with COVID-19.

Predictive Value of Systemic Immune-Inflammation index and Neutrophil-to-Lymphocyte Ratio in Patients with Severe COVID-19

Inflammation/Coagulopathy/Immunology Responsive Index Predicts Poor COVID-19 Prognosis

Systemic Immune‐inflammation Index As a Prognostic Marker for Advanced Chronic Heart Failure with Renal Dysfunction

Prognostic Value of Systemic Immune–inflammation Index in Acute/subacute Patients with Cerebral Venous Sinus Thrombosis

Systemic immune-inflammation index predicted clinical outcome in patients with aortic stenosis

The Value of SII in Predicting the Mortality of Patients with Heart Failure

Association of Systemic Immune-Inflammation Index with Short-Term Mortality of Congestive Heart Failure: A Retrospective Cohort Study

Association Between Systemic Immune-Inflammation Index and Adverse Outcomes in Patients With Acute Coronary Syndrome: A Meta-Analysis

Evaluating the prognostic value of systemic immune‐inflammatory index in patients with acute decompensated heart failure

Systemic immune-inflammation index as a novel predictor of major adverse cardiovascular events in patients undergoing percutaneous coronary intervention: a meta-analysis of cohort studies

The Role of IL-6/lymphocyte Ratio in the Peripheral Blood of Severe Patients with COVID-19.

Prognostic value of systemic immune‐inflammation index in CAD patients: Systematic review and meta‐analyses

Association between admission systemic immune-inflammation index and mortality in critically ill patients with sepsis: a retrospective cohort study based on MIMIC-IV database

Systemic Immune-Inflammatory Index Predicts Clinical Outcomes for Elderly Patients with Acute Myocardial Infarction Receiving Percutaneous Coronary Intervention

The Value of Systemic Immune-Inflammation Index and T Cell Subsets in the Severity and Prognosis of Sepsis

Systemic Immune–inflammation Index Predicts Prognosis of Cancer Immunotherapy: Systemic Review and Meta-Analysis

Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19